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The Answer Is Yes!*Piotr S. Sobieszczyk, MD, Joshua A. Beckman, MDI ntermittent claudication is the most commonsymptomatic form of peripheral artery disease(PAD). The magnitude of the disability from clau-
dication is severe, such that patients report a marked
decrease in their quality of life (1). Despite vigorous
investigative efforts, only 4 treatments reliably re-
duce disability and increase walking distance: cilos-
tazol; exercise training; percutaneous angioplasty
and stenting; and surgical bypass. Cilostazol, an oral
phosphodiesterase-3 inhibitor, modestly increases
walking distance and rarely returns patients to full
functional status (2). Therapies currently recommen-
ded most to relieve intermittent claudication include
exercise training and percutaneous revascularization.
In multispecialty expert consensus guidelines re-
leased in 2005 and reafﬁrmed in 2011, supervised
exercise training is the recommended initial treat-
ment modality for patients with intermittent claudi-
cation, with endovascular revascularization reserved
for patients who have failed exercise therapy or
have a “very favorable risk-beneﬁt ratio” (3).
Despite wide agreement of the value of supervised
exercise therapy, endovascular therapy has become,
de facto, the only treatment in the management of
patients with claudication that is due to aortoiliac
arterial disease, despite a paucity of clinical trials
supporting its durability and long-term impact on
patients’ functional status. There are several obvious
reasons why endovascular therapies are commonly
chosen. First, when successful, they make patients*Editorials published in the Journal of the American College of Cardiology
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disclose.feel better quickly. Second, the time required for
the treatment is short. Third, exercise therapy is
labor intensive, requiring a signiﬁcant investment
of time and effort by the patient and team of health-
care providers, making the process challenging (4).
Fourth, and likely most important, only endovas-
cular therapy is reimbursed in the United States.
Thus, despite a rich database demonstrating the value
of supervised exercise rehabilitation (5), it is not
routinely prescribed because it is neither reimbursed
nor available. Fifth, the beneﬁts after cessation of
the training program are unclear (6,7). Thus, at least
in part because of a lack of available options, patients
and providers have gravitated to endovascular inter-
vention as the ﬁrst-line therapy for intermittent
claudication caused by aortoiliac occlusive disease.
To clarify the value of available therapies
for claudication, Murphy et al. (8) performed the
CLEVER (Claudication: Exercise Versus Endolu-
minal Revascularization) study. This multicenter,
National Heart, Lung, and Blood Institute–sponsored
trial compared the outcomes of the 3 recommended
therapies in patients who experienced moderate-to-
severe claudication caused by aortoiliac occlusive
disease: 1) contemporary pharmacotherapy and
advice to exercise (optimal medical care [OMC]);
2) endovascular intervention and OMC; and 3)
supervised exercise and OMC. Interventional therapy
involved treatment of all aortoiliac stenoses >50%.
The exercise arm involved hour-long sessions per-
formed 3 times a week for 26 weeks. After completing
the training program, patients were provided coun-
seling by telephone, promoting exercise and pre-
venting relapse. The 6-month results of this trial were
previously published and showed improved walking
times for both supervised exercise and endovascular
revascularization (8). The exercise arm had a signiﬁ-
cantly greater peak walking time than the stenting
arm, whereas the stenting arm had a signiﬁcantly
greater increase in quality of life than the exercise
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provide a durable result comparable to endovascular
therapy remained speculative.SEE PAGE 999In this issue of the Journal, Murphy et al. (9) report
the 18-month results of the CLEVER trial. At 18
months, both supervised exercise and endovascular
therapy yielded a superior functional capacity
compared with OMC. The peak walking time and
claudication onset time improved from baseline and
remained signiﬁcantly longer among patients treated
with exercise or stenting than in the OMC arm.
Perhaps surprisingly, there was no longer a difference
between the 2 active arms: both parameters of
walking capacity improved and remained similar for
18 months, although this may be a function of the
number of patients available for follow-up. Quality of
life, measured by the disease-speciﬁc quality-of-life
metrics (Walking Impairment Questionnaire and
Peripheral Artery Questionnaire), remained signiﬁ-
cantly higher in the exercise and intervention groups
compared with the OMC arm.
The trial team must be congratulated for
completing this labor-intensive project, conducted in
29 centers over the course of 4 years. They enrolled
111 patients, and only 79 completed the 18-month
program, although the baseline characteristics of pa-
tients unavailable for follow-up were similar to those
who continued participation. These numbers high-
light some challenges in comparing therapies in an
environment in which 1 therapy is dominant because
of perception of beneﬁt, established reimbursement,
and instant gratiﬁcation. They also limit the gener-
alizability of the results. Is it possible that many
patients with aortoiliac disease were not considered
for enrollment because endovascular therapy was
considered routine, and those enrolled represented a
more complex group with less certain beneﬁt of
intervention? It is shameful that we in the vascular
community cannot muster sufﬁcient effort and in-
terest, even when resources are provided, to enroll
meaningful numbers of patients in a trial like the
CLEVER study (10).
Several important points can be gleaned from this
trial. First, both exercise training and endovascular
therapy are durable. The subjects’ adherence to ex-
ercise therapy is notable: 71% attended at least 70% of
the scheduled sessions, and 88% continued to
participate in the telephone counseling program. One
surmises that the sustained beneﬁt of exercise was, in
large part, due to motivated subjects who continued
to exercise while supported remotely by determined
study staff. Recent data suggest that telephone-basedsupport may be a viable option in getting PAD
patients to exercise (11). However, it is not certain
whether such a well-organized training and support
system can be broadly reproduced and applied.
Second, both therapies are effective in patients
with intermittent claudication from aortoiliac occlu-
sive disease. The current paradigm favors a quick
and moderate improvement in walking distance with
a signiﬁcant improvement in quality of life at the
expense of signiﬁcantly greater increase in walking
distance. The lack of reimbursement for exercise
therapy is particularly distressing, for it presumes that
“1 size ﬁts all.” This is particularly irksome, because
exercise has ancillary beneﬁts, with reductions in
blood pressure, improvements in the lipid proﬁle,
and better glucose control—all standard recommen-
dations for patients with atherosclerosis. We strongly
advocate research to identify patients for whom one
therapy would be recommended ﬁrst over the other.
Third, it is time to end the competition between
therapies. This well-done trial makes clear that su-
pervised exercise and percutaneous revascularization
have different mechanisms of action and different
treatment outcomes—both of which are desirable. In
contrast to pitting one treatment against the other, it
might be better to treat claudication like hyperten-
sion, where practitioners use as many therapies as
needed to bring the patient to goal. The goal in
patients with claudication is to minimize (to 0 if
possible) the disability caused by claudication. Cil-
ostazol, supervised exercise therapy with follow-up
telephone monitoring, and endovascular revascular-
ization are complementary, should be used as needed
in appropriate patients, and applied until the patient
is better.
A ﬁnal observation is that the trial evaluated
a therapy currently unavailable in the United States.
The CLEVER trial established that supervised exer-
cise is at least as effective as endovascular interven-
tion. Despite the existing infrastructure for cardiac
and pulmonary rehabilitation programs, exercise
therapy remains unavailable for patients with PAD
and intermittent claudication, even though it is less
expensive than intervention (12). The demonstration
that the results are durable in patients with claudi-
cation in the CLEVER study should spur a change in
coverage by federal and private insurers to make su-
pervised exercise therapy and follow-up care avail-
able to all patients who need them.
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